Related Experiment Video
Updated: Jun 4, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Proteomic analysis of cell lines to identify the irinotecan resistance proteins
Xing-Chen Peng1, Feng-Ming Gong, Meng Wei
1Department of Medical Oncology, Cancer Center, and The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China.
Abstract:
Chemotherapeutic drug resistance is a frequent cause of treatment failure in colon cancer patients. Several mechanisms have been implicated in drug resistance. However, they are not sufficient to exhaustively account for this resistance emergence. In this study, two-dimensional gel electrophoresis (2-DE) and the PDQuest software analysis were applied to compare the differential expression of irinotecan-resistance-associated protein in human colon adenocarcinoma LoVo cells and irinotecan-resistant LoVo cells (LoVo/irinotecan). The differential protein dots were excised and analysed by ESI-Q-TOF mass spectrometry (MS). Fifteen proteins were identified, including eight proteins with decreased expression and seven proteins with increased expression. The identified known proteins included those that function in diverse biological processes such as cellular transcription, cell apoptosis, electron transport/redox regulation, cell proliferation/differentiation and retinol metabolism pathways. Identification of such proteins could allow improved understanding of the mechanisms leading to the acquisition of chemoresistance.
Insights
Chemotherapeutic drug resistance in colon cancer is a major challenge. This study identified 15 proteins associated with irinotecan resistance in colon cancer cells, offering new insights into chemoresistance mechanisms.
Area of Science:
- Proteomics
- Cancer Biology
- Molecular Oncology
Background:
- Chemotherapeutic drug resistance frequently leads to treatment failure in colon cancer.
- Existing mechanisms do not fully explain the emergence of drug resistance.
- Understanding novel resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To compare protein expression profiles between human colon adenocarcinoma LoVo cells and their irinotecan-resistant counterparts (LoVo/irinotecan).
- To identify proteins associated with irinotecan resistance in colon cancer.
- To elucidate potential mechanisms underlying chemoresistance acquisition.
Main Methods:
- Two-dimensional gel electrophoresis (2-DE) coupled with PDQuest software analysis was used for differential protein expression analysis.
- Differentially expressed protein spots were excised and analyzed using ESI-Q-TOF mass spectrometry (MS).
- Proteomic analysis was performed on LoVo and LoVo/irinotecan cell lines.
Main Results:
- Fifteen proteins showed differential expression between sensitive and resistant colon cancer cells.
- Eight proteins exhibited decreased expression, while seven proteins showed increased expression in resistant cells.
- Identified proteins are involved in critical cellular processes including transcription, apoptosis, redox regulation, proliferation, and retinol metabolism.
Conclusions:
- The study identified novel proteins linked to irinotecan resistance in colon cancer.
- These findings contribute to a better understanding of the molecular mechanisms driving chemoresistance.
- Further investigation of these proteins may reveal new therapeutic targets for overcoming drug resistance in colon cancer.
